Livanova Plc  (LIVN)
Other Ticker:  
Price: $45.9200 $1.07 2.386%
Day's High: $46.06 Week Perf: 0.15 %
Day's Low: $ 44.66 30 Day Perf: -8.23 %
Volume (M): 713 52 Wk High: $ 59.86
Volume (M$): $ 32,750 52 Wk Avg: $50.62
Open: $44.66 52 Wk Low: $40.26

 Market Capitalization (Millions $) 2,479
 Shares Outstanding (Millions) 54
 Employees 4,000
 Revenues (TTM) (Millions $) 1,118
 Net Income (TTM) (Millions $) 3
 Cash Flow (TTM) (Millions $) 26
 Capital Exp. (TTM) (Millions $) 31

Livanova Plc
Livanova Plc is a diversified medical technology company that is committed to improving patient outcomes and reducing the cost of healthcare in the areas of cardiovascular and neuromodulation treatment. The company was formed in 2015, as a result of a merger between Cyberonics Inc. and Sorin Group.

Headquartered in London, Livanova operates in over 100 countries worldwide, with its primary focus being on the development, manufacture, and marketing of medical devices used in the treatment of various heart and neurological conditions. It has over 3,500 employees working across its various manufacturing and research facilities in the United States, Europe, and Asia-Pacific.

Livanova's Cardiovascular business segment offers a range of products that include heart-lung equipment, oxygenators, perfusion systems, cannulae, and devices used in extracorporeal membrane oxygenation (ECMO) therapy. Its pioneering ECMO technology is widely recognized and used for treating life-threatening cardiopulmonary failure in neonatal and pediatric patients. The company's implantable cardiac rhythm management products, including pacemakers, defibrillators, and cardiac resynchronization therapy devices, are designed to manage cardiac arrhythmias and heart failure.

The Neuromodulation business segment of Livanova provides products for the treatment of patients with epilepsy, depression, chronic pain, and other neurological disorders. Its Vagus Nerve Stimulation (VNS) Therapy System is a revolutionary device that delivers electrical stimulation to the vagus nerve, offering relief to patients with epilepsy and depression who have not responded to traditional treatments. The segment also produces Deep Brain Stimulation (DBS) Systems, which can reduce symptoms of movement disorders such as Parkinson's disease.

Livanova Plc is dedicated to research and development, with a strong pipeline of new products and technological innovation. They continually invest in research and development and have a strong focus on profitability and growth. They have a strong corporate culture, and their core values include focusing on patients, working collaboratively, continuous improvement, and maintaining a high level of ethical conduct.

In conclusion, Livanova Plc is a global leader in the development and manufacture of medical technology that improves the lives of people with heart and neurological conditions. With a dedicated team, strong product pipeline, and a commitment to innovation, Livanova is well-positioned to grow in the medical device market for many years to come.

   Company Address: 20 Eastbourne Terrace London 0
   Company Phone Number: 203 325-0660   Stock Exchange / Ticker: NASDAQ LIVN
   LIVN is expected to report next financial results on February 26, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Aurora Technology Acquisition Corp

Aurora Technology Acquisition Corp Faces Declining Operating Behavior, Raising Concerns in Q3 2023

An Overview of Aurora Technology Acquisition Corp's Third Quarter Earnings
As the July to September 30, 2023 earnings season progresses, various companies across different industries are reporting their financial results. One such industry is the Medical Equipment and Supplies sector, which has seen many corporations release their earnings reports. Among them is Aurora Technology Acquisition Corp (ATAK), which recently announced an operating deficit of -$0.4793 million for the third quarter of 2023.
Comparing this figure to the same period in 2022, we can observe a deteriorating operating deficit. In the third quarter of 2022, ATAK reported an operating deficit of -$0.21933 million. This decline raises questions among market participants about the company's ability to generate revenue.

Vivos Therapeutics Inc

Vivos Therapeutics Inc. Defies Financial Odds in the Demanding Times of September 2023

For the fiscal time-frame closing September 30 2023 Vivos Therapeutics Inc decreased a loss per share of $-1.75 per share compare to $-6.50 a year before and Income per Share improved from $-4.50 per share from the preceding reporting season. The revenue crumbled by -31.748 % to $2.90 million from $4.25 million in the corresponding reporting season a year before and sequentially Revenue decreased by -6.456 % from $3.10 million.

Vystar Corporation

Devastating Blow: Medical Equipment and Supplies Company Suffers Major Setback in Q3 2023 Financial Report

Over the past five days, Vystar Corporation has experienced a significant drop in its stock price, declining by -37.78%. Furthermore, the stock is currently trading -20.9% below its 52-week average. In order to better understand the reasons behind this decline, it is essential to examine Vystar Corporation's financial performance for the recent reporting season, which ended on September 30, 2023.
Earnings Per Share and Revenue:
Vystar Corporation reported a considerable improvement in its financial health compared to the previous year. The loss per share decreased from $-0.23 to $-0.03, while the income per share improved from $-0.04. In terms of revenue, there was a significant decline of -98.311% from $3.57 million to $0.06 million compared to the same reporting season a year prior. However, sequentially, the revenue saw an increase of 67.054% from $0.04 million.

Petvivo Holdings Inc

Petvivo Holdings Inc Experiences Widening Losses in Q2 2024 Amid Decrease in Orders

As an investor closely following Petvivo Holdings Inc, the recent financial results have presented a mixed bag of challenges and opportunities. In the second quarter of 2024, the company experienced lower turnover, resulting in a significant revenue decrease and a larger shortfall per share compared to the previous year. However, there were notable signs of potential growth and increasing demand within the Medical Equipment and Supplies industry.
One of the key financial indicators is the revenue, which decreased by -7.127% to $0.21 million year on year. This decline is concerning for Petvivo Holdings Inc, as it points to potential shortcomings in the company's ability to generate sales. Comparatively, the Medical Equipment and Supplies industry as a whole recorded a top-line rise in the same period, suggesting that Petvivo may be facing certain internal challenges.

Ir Med Inc

Ir Med Inc announced operating profit of $1.197 million, in the third quarter of 2023 financial report

As an observer of the Medical Equipment and Supplies sector, I have thoroughly analyzed the third quarter financial results of Ir Med Inc. The company's performance took center stage in this report, overshadowing the same period in the previous year. Despite operating predominantly in the development phase, Ir Med Inc showcased a bullish quarter, signaling potential growth prospects.
Notably, Ir Med Inc reported an operating profit of $1.197 million for the July to September 30, 2023 quarter, without any reported revenue. This indicates that the company is focusing on developing its services rather than generating immediate revenue. Such a strategic course of action is crucial for a business aiming to establish a strong foundation before entering the market.


Livanova Plc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com